Moderna, Inc.
Moderna, Inc. discovers and develops mRNA therapeutics and vaccines for various diseases. It has respiratory, latent, public health, and infectious disease vaccines. The company also offers systemic, cancer, intratumoral, rare disease, and pulmonary therapeutics. Moderna has strategic alliances with several companies, including AstraZeneca, Merck & Co., Vertex Pharmaceuticals, and Chiesi Farmaceutici. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts. It changed its name from Moderna Therapeutics to Moderna, Inc. in August 2018.
Overview
Strengths
- High-quality earnings: over the last 7 years, free cash flow added up to 115% of reported net income.
- Scale advantage: ranks #3 by enterprise value ($94 billion) among the 129 Biotechnology companies we cover.
Weaknesses
- Operating profit does not cover interest expense.
- Eroding returns: ROIC has fallen to 0.0% from a multi-year average of 26.8%, a possible sign of a weakening moat.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 4 of the last 7 years.
- Unstable profitability: operating margin ranged from -1,136% to 75% over the last 7 years, with operating losses in 5 of them.
Key Financial Data